Frontline and Subsequent Therapies for Chronic Lymphocytic Leukemia

home / case-based-roundtable-series / frontline-and-subsequent-therapies-for-chronic-lymphocytic-leukemia

This roundtable series assesses the use of Bruton tyrosine kinase inhibition for patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia, as discussed by participants at virtual live events.

Choosing BTK Inhibitors Versus Venetoclax as First-Line CLL Therapy

Choosing BTK Inhibitors Versus Venetoclax as First-Line CLL Therapy

Nilanjan Ghosh, MD
April 1st 2022

Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.

Acalabrutinib With/Without Obinutuzumab Shows Survival Benefit in CLL

Acalabrutinib With/Without Obinutuzumab Shows Survival Benefit in CLL

Farrukh Awan, MBBS
May 16th 2022

Farrukh Awan, MD, discusses the results of the phase 3 ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLL

Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLL

Nakhle Saba, MD
June 10th 2022

Nakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.